21 stories
All topics
Gavi reported that HPV vaccination in lower-income countries has protected 86 million girls and is estimated to prevent 1.4 million cervical cancer deaths — with over a million already averted — reaching a major coverage target ahead of schedule.
Sir Adrian Hill of Oxford’s Jenner Institute received the 2026 European Inventor Award for the R21/Matrix-M malaria vaccine, a low-cost shot with 75–80% efficacy now being rolled out across more than 20 African countries.
On 8 May 2026, the WHO reported that malaria vaccines averted roughly one in eight deaths among eligible young children in Ghana, Kenya and Malawi — powerful evidence as the vaccines reach 25 African countries.
New evidence published in The Lancet and announced by the WHO on 8 May 2026 found that the RTS,S malaria vaccine averted about one in eight child deaths in Ghana, Kenya and Malawi over four years, confirming its life-saving impact.
The WHO’s Big Catch-Up initiative delivered more than 100 million vaccine doses to 18.3 million children across 36 countries between 2023 and 2025, including 12.3 million who had never received any vaccine.
A five-year vaccination project at Elanora on the Gold Coast has immunized more than 500 koalas against chlamydia, cutting disease-related hospital admissions by 75 percent. Once-devastated koalas are now thriving, with 41 joeys and 13 “grand-joeys” born.
At the 2026 AACR meeting, Memorial Sloan Kettering researchers reported that a personalized mRNA pancreatic-cancer vaccine triggered immune responses lasting up to six years, with most responders still alive — a hopeful sign against one of the deadliest cancers.
A joint WHO–Gavi analysis released in April 2026 found that measles vaccination averted nearly 20 million deaths in Africa between 2000 and 2024, as coverage rose from 5% to 55% across the region.
An mRNA-based malaria vaccine developed by Oxford and BioNTech has demonstrated 95% efficacy in a Phase 3 trial involving 22,000 children across six African nations, far surpassing existing vaccines and offering hope for eliminating the disease.
A study of over 246,000 adults with heart disease found that shingles vaccination was associated with a 46% reduction in major cardiac events and a 66% reduction in all-cause mortality within one year.
Research shows the shingles vaccine may double as a heart protector, cutting major cardiac events by 46% and deaths by 66% within a year in people already at high cardiovascular risk.
On 28 February 2026, India launched a free nationwide HPV vaccination campaign for 14-year-old girls, aiming to protect millions and sharply cut its heavy burden of cervical cancer.
A single-dose vaccine targeting a conserved region of the influenza virus provided 88% protection across all strains for at least three years in a 25,000-person trial.
A major new study has identified three familiar medicines — including the shingles vaccine — that could take on an unexpected new role in the fight against Alzheimer's disease, offering hope to the millions of families affected worldwide.
The groundbreaking malaria vaccine has now been administered to 10 million children across Africa, dramatically reducing deaths from one of humanity oldest killers.
A study of nearly 14 million children in England reveals that Covid infection carries a substantially higher risk of heart complications than vaccination.
Scientists at Melbourne's Doherty Institute used mRNA technology to force HIV out of hiding in white blood cells, a critical step toward a cure. The technique encases HIV in a "fat bubble" nanoparticle that reveals the virus to the immune system.
Real-world studies from the 2024-2025 season found that the antibody nirsevimab and the maternal RSV vaccine sharply reduced infant hospitalizations for respiratory syncytial virus, in some age groups by more than half.
Researchers at the University of Florida developed an mRNA cancer vaccine that supercharges the immune system to recognize and attack cancer cells, paving the way for a potential universal cancer treatment.
The Phase 3 trial of the M72/AS01E tuberculosis vaccine reached full enrollment of about 20,000 people in April 2025, raising hopes for the first new TB vaccine in a century after an earlier trial showed roughly 50% efficacy.
A UN report released in March 2025 found that deaths of children under five fell to 4.8 million in 2023, less than half the level of 2000, a milestone driven by vaccines, nutrition and clean water.
